Modified Vaccinia Ankara (MVA) Shows Promising Efficacy in Renal Cell Cancer Treatment

Strategic Insights -

A team of researchers from the University of Texas conducted a phase 2 trial to evaluate the safety and efficacy of a novel cancer vaccine, MVA-5T4, in patients with metastatic renal cell cancer. The vaccine, which combines the attenuated vaccinia virus with the tumor antigen 5T4, was administered alone or in combination with interferon-alpha-2b to 28 patients. The study found that 22 out of 23 patients who received the vaccine developed 5T4-specific antibody and/or cellular responses, with one patient showing a partial response for 7 months and 14 patients experiencing periods of disease stabilization. The researchers concluded that the results were encouraging and warranted further investigation.

Key Takeaways:

  • The MVA-5T4 vaccine was well-tolerated in all patients, with 110 serious adverse events attributed to vaccination.
  • 22 out of 23 patients who received the vaccine developed 5T4-specific antibody and/or cellular responses.
  • One patient showed a partial response for 7 months, while 14 patients experienced periods of disease stabilization.
  • Median progression-free survival and overall survival for all intent-to-treat patients were 3.8 months and 12.1 months, respectively.
  • The vaccine was effective in inducing 5T4-specific immune responses, but it is unclear whether this translated to clinical benefit for patients.
  • The study suggests that further investigation into the use of MVA-5T4 as a treatment for renal cell cancer is warranted.
  • The University of Texas researchers collaborated with other institutions to conduct the phase 2 trial.

Statistics:

  • 110 serious adverse events were attributed to vaccination.
  • 22 out of 23 patients developed 5T4-specific antibody and/or cellular responses (96% response rate).
  • Median progression-free survival was 3.8 months (range: 1 to 11.47mo).
  • Median overall survival was 12.1 months (range: 1 to 27 mo).
  • 28 patients were treated with MVA-5T4 alone or in combination with interferon-alpha-2b.
  • 14 patients experienced periods of disease stabilization (ranging from 1.73 to 9.60 months).

Sources:

  • R.J. Amato et al., "Vaccination of Renal Cell Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Alone or Administered in Combination With Interferon-alpha (IFN-alpha) A Phase 2 Trial," Journal of Immunotherapy, 2009;32(7):765-772.
  • University of Texas Health Science Center, Mem Hermann Cancer Center, 6410 Fannin, Suite 722, Houston, TX 77030, USA.
  • Lippincott Williams & Wilkins, 530 Walnut St., Philadelphia, PA 19106-3621, USA.